Revvity, Inc. is set to announce its quarterly earnings on Monday, May 4th, with a consensus estimate EPS of 1.02.
Revvity, Inc. (RVTY) is currently priced at $85.12, showing a price decrease of $1.68 (-1.94%) from the previous close. The trading volume stands at $325,517, representing a 27.1% increase relative to the average.
In the latest quarterly earnings report released on Sunday, February 1st, Revvity, Inc. reported a consensus estimate EPS of 1.55. The earnings date for the upcoming report is highlighted.
Revvity, Inc. offers a forward dividend yield of 0.329% with a dividend per share of 7 cents MRQ and 35 cents TTM. There has been no change in the dividend per share YoY.
Key financial ratios for Revvity, Inc. include a gross profit margin of 43.8%, operating profit margin of 14.47%, and net profit margin of 12.74%. Notable ratios like return on equity (1.36) and price-to-earnings ratio (27.94) provide insights into the company's financial performance.
This real-time financial report on Revvity, Inc. (RVTY) offers a snapshot of its current status and upcoming financial outlook, providing investors with valuable insights for decision-making.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.